Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Idiopathic pulmonary fibrosis, a progressive and inevitably fatal disorder, has a highly variable clinical course. Biomarkers that reflect disease activity are urgently needed to inform patient management and for use as biomarkers of therapeutic response (theragnostic biomarkers) in clinical trials. We aimed to determine whether dynamic change in markers of extracellular matrix (ECM) turnover predicts progression of idiopathic pulmonary fibrosis as determined by change in forced vital capacity and death.
Date Issued
2015-06
Date Acceptance
2015-03-12
Citation
Lancet Respiratory Medicine, 2015, 3 (6), pp.462-472
ISSN
2213-2619
Publisher
Elsevier: Lancet
Start Page
462
End Page
472
Journal / Book Title
Lancet Respiratory Medicine
Volume
3
Issue
6
Copyright Statement
© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Subjects
Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
Respiratory System
General & Internal Medicine
FORCED VITAL CAPACITY
MATRIX-METALLOPROTEINASE
BIOCHEMICAL MARKERS
MANAGEMENT
MORTALITY
STATEMENT
DIAGNOSIS
PROTEINS
EFFICACY
FUTURE
Aged
Biomarkers
Cohort Studies
Collagen
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Idiopathic Pulmonary Fibrosis
Longitudinal Studies
Male
Matrix Metalloproteinases
Prospective Studies
Publication Status
Published
Date Publish Online
2015-03-12